AHA Issues Pediatric Hypertriglyceridemia Statement
The scientific statement defines pancreatitis and atherosclerotic cardiovascular disease risk thresholds and outlines causes and management in youths.
By
Kathryn Wighton
February 26, 2026
Objective: To outline the screening, diagnosis, and management of pediatric hypertriglyceridemia.
Key Findings: Severe hypertriglyceridemia increases the risk of acute pancreatitis and atherosclerotic cardiovascular disease. Lifestyle modifications can significantly reduce triglyceride levels in affected youths. Pharmacotherapy is rarely indicated and should be considered for persistent high levels despite lifestyle changes. Interpretation: Early detection and lifestyle interventions are crucial for managing pediatric hypertriglyceridemia, with pharmacotherapy reserved for specific cases.
Limitations: Lack of FDA-approved medications specifically for pediatric hypertriglyceridemia. Need for more research on the safety and efficacy of treatments in children. Conclusion: The statement emphasizes the importance of lifestyle changes and the need for further research in pediatric hypertriglyceridemia management.
